Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by GoBBson May 05, 2020 8:35pm
77 Views
Post# 30990684

RE:RE:spammers working hard on this board, why are they here?

RE:RE:spammers working hard on this board, why are they here?I'm only responding to this because I posted this originally and Newcamo then started using it everyday certainly not coming to the moron's aid lol...

Its in the MD&A on Sedar Nov 12, 2019 English version, page 11 of 44 ...

For 1. , validated by who ?
For 5.., so they have been doing Data Analysis and preparing docs for Dec 19 - May 20 ? 6 months ???? Please, it smells a lot.



"In early 2019 the Company established the following critical path towards regulatory approval for RyplazimTM in the U.S. is as follows:
1. Development and validation of new analytical assays and in-process controls (complete)
2. Finalization of PPQ protocol (complete)
3. Manufacturing of additional conformance lots (complete)
4. Fill & Finish at external Contract Manufacturing Organization (“CMO”) (complete)
5. Data analysis & preparation of required documents for FDA (in process)
6. Regulatory filing of BLA amendment documents – now likely to take place in H1 2020
7. Anticipated new PDUFA date after the acceptance of the amended BLA"
<< Previous
Bullboard Posts
Next >>